Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.
McCann KJ, Mander A, Cazaly A, Chudley L, Stasakova J, Thirdborough S, King A, Lloyd-Evans P, Buxton E, Edwards C, Halford S, Bateman A, O'Callaghan A, Clive S, Anthoney A, Jodrell DI, Weinschenk T, Simon P, Sahin U, Thomas GJ, Stevenson FK, Ottensmeier CH. McCann KJ, et al. Among authors: anthoney a. Clin Cancer Res. 2016 Oct 1;22(19):4827-4836. doi: 10.1158/1078-0432.CCR-15-2507. Epub 2016 Apr 18. Clin Cancer Res. 2016. PMID: 27091407 Free PMC article. Clinical Trial.
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Melcher A, Nicholls J, Wassan H, Habib N, Anthoney A. Harrop R, et al. Among authors: anthoney a. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4487-94. doi: 10.1158/1078-0432.CCR-07-0704. Clin Cancer Res. 2007. PMID: 17671134 Clinical Trial.
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Middleton MR, McAlpine C, Woodcock VK, Corrie P, Infante JR, Steven NM, Evans TRJ, Anthoney A, Shoushtari AN, Hamid O, Gupta A, Vardeu A, Leach E, Naidoo R, Stanhope S, Lewis S, Hurst J, O'Kelly I, Sznol M. Middleton MR, et al. Among authors: anthoney a. Clin Cancer Res. 2020 Nov 15;26(22):5869-5878. doi: 10.1158/1078-0432.CCR-20-1247. Epub 2020 Aug 18. Clin Cancer Res. 2020. PMID: 32816891 Free PMC article. Clinical Trial.
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
Jones R, Plummer R, Moreno V, Carter L, Roda D, Garralda E, Kristeleit R, Sarker D, Arkenau T, Roxburgh P, Walter HS, Blagden S, Anthoney A, Klencke BJ, Kowalski MM, Banerji U. Jones R, et al. Among authors: anthoney a. Clin Cancer Res. 2023 Jan 17;29(2):331-340. doi: 10.1158/1078-0432.CCR-22-2074. Clin Cancer Res. 2023. PMID: 36378548 Free PMC article. Clinical Trial.
Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.
Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N, Alcock C, Anthoney A, Vjaters E, Dunk CR, Harris PA, Wong A, Lalani AS, Twelves CJ. Albertella MR, et al. Among authors: anthoney a. Clin Cancer Res. 2008 Feb 15;14(4):1096-104. doi: 10.1158/1078-0432.CCR-07-4020. Clin Cancer Res. 2008. PMID: 18281542 Free article. Clinical Trial.
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.
Blagden S, Omlin A, Josephs D, Stavraka C, Zivi A, Pinato DJ, Anthoney A, Decordova S, Swales K, Riisnaes R, Pope L, Noguchi K, Shiokawa R, Inatani M, Prince J, Jones K, Twelves C, Spicer J, Banerji U. Blagden S, et al. Among authors: anthoney a. Clin Cancer Res. 2014 Dec 1;20(23):5908-17. doi: 10.1158/1078-0432.CCR-14-1315. Epub 2014 Sep 17. Clin Cancer Res. 2014. PMID: 25231405 Free PMC article. Clinical Trial.
Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery.
West E, Morgan R, Scott K, Merrick A, Lubenko A, Pawson D, Selby P, Hatfield P, Prestwich R, Fraser S, Eves D, Anthoney A, Twelves C, Beirne D, Patel P, O'Donnell D, Watt S, Waller M, Dietz A, Robinson P, Melcher A. West E, et al. Among authors: anthoney a. J Immunother. 2009 Jan;32(1):66-78. doi: 10.1097/CJI.0b013e31818be071. J Immunother. 2009. PMID: 19307995
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, Cunningham D, Falk S, Wadd N, Harrison M, Corrie P, Iveson T, Robinson A, McAdam K, Eatock M, Evans J, Archer C, Hickish T, Garcia-Alonso A, Nicolson M, Steward W, Anthoney A, Greenhalf W, Shaw V, Costello E, Naisbitt D, Rawcliffe C, Nanson G, Neoptolemos J. Middleton G, et al. Among authors: anthoney a. Lancet Oncol. 2014 Jul;15(8):829-40. doi: 10.1016/S1470-2045(14)70236-0. Epub 2014 Jun 19. Lancet Oncol. 2014. PMID: 24954781 Free article. Clinical Trial.
69 results